About this trial
This study aims to address the issue of a lack of individualized basis for selecting liver resection (LH) or microwave ablation (MWA) in early-stage hepatocellular carcinoma (HCC) patients to reduce the early recurrence rate (≤2 years). Given that existing machine learning-based recurrence prediction studies have failed to guide the optimal treatment plan selection, and that multidisciplinary consultations rely on guidelines (universality) and experience (subjectivity) which have their limitations, we propose to utilize artificial intelligence (AI), specifically the advantages of multimodal deep learning technology (which outperforms traditional machine learning by integrating complementary information to provide more accurate predictions), to establish a hybrid deep learning model that integrates contrast-enhanced ultrasound (CEUS) and enhanced magnetic resonance imaging (MRI) features. This model will predict the probability of early recurrence (ER≤2 years) in patients and, based on this, recommend LH or MWA as the optimal first treatment option for newly diagnosed early HCC patients to optimize individualized treatment decisions.
Eligibility criteria
Qualifiers
Preoperative enhanced imaging examination or pathological diagnosis is HCC;
CNLC Stage I, IIa, Child-Pugh Class A/B;
A single tumor with a diameter ≤ 5 cm or 2-3 tumors, with the maximum diameter ≤ 3 cm;
Perform liver resection surgery or MWA surgery treatment;
Disqualifiers
None
Trial design
Treatments tested in this trial
- surgery
- ablation
Treatment groups
Sponsors and collaborators
The First Hospital of Jilin University
Lead sponsor
Chinese PLA General Hospital
Collaborator